Last Updated: June 2026
Published by: Saif Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Farhan Hossain, MBBS, MD (Oncology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from the FDA, EMA, and DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: accessdata.fda.gov, fda.gov, accessdata.fda.gov, drugs.com, accessdata.fda.gov
Key Takeaways
- Talazoparib is a PARP inhibitor that works through a dual mechanism — blocking PARP enzymes and physically trapping PARP proteins on damaged DNA — making it particularly effective against tumors with germline BRCA mutations.
- It is approved for two distinct indications: germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer as a single agent, and HRR gene-mutated metastatic castration-resistant prostate cancer in combination with enzalutamide.
- In the pivotal breast cancer trial, talazoparib demonstrated a statistically significant improvement in progression-free survival compared with standard chemotherapy, with a hazard ratio of 0.54 — representing a clinically meaningful reduction in the risk of disease progression or death.
- Patient selection for the breast cancer indication requires confirmation of a germline BRCA mutation using the FDA-approved BRACAnalysis CDx companion diagnostic test prior to initiating therapy.
- The safety profile includes common reactions such as fatigue, anemia, and neutropenia, as well as serious risks including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and embryo-fetal toxicity, requiring appropriate monitoring and clinical management.
- Talazoparib capsules — manufactured by Everest Pharmaceuticals Ltd. in Bangladesh — provide procurement teams in Saudi Arabia and the Middle East with a supply pathway for this internationally validated oncology agent; available strengths should be confirmed directly with the supplier, with 0.25 mg and 1 mg capsules manufactured by Everest Pharmaceuticals Ltd.
What Is Talazoparib and How Does It Work?
Talazoparib is a targeted oncology agent classified as a poly (ADP-ribose) polymerase (PARP) inhibitor — a therapeutic class that has reshaped the treatment landscape for genetically defined cancers. PARP enzymes play a central role in cancer cell growth, regulation, and DNA repair. By blocking these enzymes, talazoparib disrupts the repair mechanisms that cancer cells depend on for survival.
What distinguishes talazoparib within the PARP inhibitor class is its dual mechanism of action. Beyond enzymatic inhibition, talazoparib physically traps PARP proteins on damaged DNA strands. This trapping effect prevents the cancer cell from completing DNA repair, ultimately triggering cell death. In tumors harboring germline BRCA mutations — where a secondary DNA repair pathway is already compromised — this mechanism is particularly lethal to malignant cells while sparing normal tissue to a comparatively greater degree.
Mechanism of Action: Synthetic Lethality in BRCA-Mutated Cancers
The synthetic lethality principle underpins the clinical rationale for talazoparib as a PARP inhibitor in BRCA-mutated cancers. In normal cells, DNA damage can be repaired through multiple pathways, including both PARP-mediated base excision repair and BRCA-mediated homologous recombination. However, in cells with germline BRCA mutations, the homologous recombination pathway is already defective. When PARP is additionally inhibited by talazoparib, cancer cells lose both major DNA repair mechanisms, leading to accumulation of DNA damage and cell death — a phenomenon known as synthetic lethality.
This scientifically grounded mechanism makes talazoparib particularly effective in molecularly selected patient populations, representing a paradigm shift from traditional cytotoxic chemotherapy toward precision oncology approaches based on tumor genetics.
Understanding this mechanism is essential for medical affairs and procurement teams evaluating targeted oncology portfolios. For broader context on genetic oncology and how genomic mutations drive cancer biology, additional resources are available.
Approved Indications: gBRCAm Breast Cancer and mCRPC
Talazoparib carries two distinct approved indications, each addressing a genetically defined patient population with significant unmet clinical need.
Germline BRCA-Mutated HER2-Negative Breast Cancer
As a single agent, talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Patient selection for this indication requires the use of an FDA-approved companion diagnostic — specifically the BRACAnalysis CDx test — to confirm the presence of a germline BRCA mutation prior to initiating therapy.
Companion Diagnostic Requirement: The BRACAnalysis CDx test is not merely recommended but required for patient selection in the breast cancer indication. This companion diagnostic requirement ensures that only patients most likely to benefit from the PARP inhibitor mechanism are selected for treatment, reflecting the precision medicine approach that defines modern oncology practice.
HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Talazoparib is also approved in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer. This indication extends the clinical utility of talazoparib beyond breast cancer, addressing a molecularly defined subset of mCRPC patients — an area of growing clinical and procurement interest, often referenced in searches for talazoparib prostate cancer applications.
The mCRPC indication represents the expansion of PARP inhibitor therapy into male malignancies with DNA repair deficiencies. HRR gene mutations include alterations in BRCA1, BRCA2, ATM, and other genes involved in homologous recombination, creating a similar synthetic lethality opportunity as seen in breast cancer.
Together, these two indications reflect the expanding role of PARP inhibitor talazoparib across multiple tumor types defined by DNA repair pathway deficiencies, reinforcing its relevance in precision oncology formularies.
Clinical Evidence Supporting Talazoparib
The clinical validation of talazoparib in germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer is supported by robust efficacy data that formed the basis of its regulatory approval.
Pivotal Breast Cancer Trial: EMBRACA Study
In the pivotal breast cancer trial (EMBRACA), talazoparib demonstrated a median progression-free survival (PFS) of 8.6 months compared with 5.6 months for patients receiving standard chemotherapy (physician’s choice of capecitabine, eribulin, gemcitabine, or vinorelbine). This difference corresponded to a hazard ratio of 0.54 (95% CI: 0.41–0.71; p<0.0001), indicating a statistically significant and clinically meaningful 46% reduction in the risk of disease progression or death.
Clinical Significance and Study Design
- Study Design: Phase 3, randomized, open-label, multicenter trial
- Patient Population: 431 patients with germline BRCA1/2 mutations and HER2-negative advanced breast cancer
- Primary Endpoint: Progression-free survival by blinded independent central review
- Statistical Significance: The p-value of <0.0001 indicates extremely strong statistical evidence
- Clinical Magnitude: The near-doubling of median PFS represents a clinically meaningful benefit in this patient population
Clinical Context for Procurement Decision-Makers
For procurement professionals and hospital formulary committees in Saudi Arabia and across the Middle East, this level of clinical evidence provides a strong foundation for evaluating talazoparib within oncology drug budgets and treatment protocols. The EMBRACA trial data demonstrates:
- Superiority over standard chemotherapy in a molecularly defined population
- Consistent benefit across subgroups including hormone receptor status and prior lines of therapy
- Oral administration offering potential advantages in patient convenience and healthcare resource utilization
- Biomarker-driven patient selection ensuring appropriate use and optimizing value
The data aligns with the broader shift toward biomarker-driven therapy selection, where companion diagnostics such as BRACAnalysis CDx are integral to patient identification and treatment planning. This evidence base, combined with the talazoparib approval by the FDA in 2018, positions the molecule as a well-validated option within the global precision oncology landscape.
Product Specifications: Talaparib Capsules by Everest Pharmaceuticals
The talazoparib product available through our supply chain is manufactured under the brand name Talaparib by Everest Pharmaceuticals Ltd. (Bangladesh). This Bangladeshi-manufactured formulation is produced as hard capsules intended for oral administration.
Available Strengths
- 0.25 mg capsule
- 1 mg capsule
Clinical Flexibility and Dosing Considerations
The availability of two distinct capsule strengths supports clinical flexibility in patient management, particularly where dose adjustments may be required based on individual patient factors including:
- Renal function: Dose reduction recommended for moderate or severe renal impairment
- Hematologic toxicity: Dose modifications may be necessary for anemia, neutropenia, or thrombocytopenia
- Concomitant medications: Drug interactions may necessitate dose adjustments
- Tolerability: Individual patient tolerance may require dose optimization
Administration guidance: Capsules should be swallowed whole and not opened, chewed, or dissolved. Specific dosing regimens and any modifications are determined exclusively by the treating physician in accordance with the official prescribing information.
The talazoparib molecule received FDA approval in 2018, establishing a globally recognized regulatory benchmark for this active pharmaceutical ingredient. Talaparib capsules by Everest Pharmaceuticals represent a Bangladeshi-manufactured supply option aligned with this internationally validated molecule, offering procurement teams in Saudi Arabia and the broader Middle East a reliable sourcing pathway for this targeted oncology agent.
Regulatory Context for the Middle East and Saudi Arabia
For procurement teams and medical affairs professionals operating in the Kingdom of Saudi Arabia, understanding the regulatory framework surrounding talazoparib is essential for informed sourcing decisions.
International Regulatory Milestones
Talazoparib received FDA approval in October 2018, making it one of the earlier PARP inhibitors to achieve regulatory clearance in the United States for the breast cancer indication. The FDA approval serves as a globally recognized benchmark and is routinely referenced by procurement authorities across the Middle East when evaluating the credentialing of oncology medicines for hospital formularies, tender submissions, and institutional procurement.
- FDA Approval Date: October 16, 2018
- Approval Pathway: Priority Review designation
- Regulatory Basis: EMBRACA Phase 3 trial demonstrating superior PFS vs. chemotherapy
- Companion Diagnostic: BRACAnalysis CDx approved concurrently
Saudi Arabia Regulatory Framework
In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) is the national regulatory body responsible for the registration and oversight of pharmaceutical products. The SFDA operates under the framework of the Gulf Cooperation Council (GCC) centralized registration system while maintaining authority for national registration decisions.
Considerations for KSA Procurement Teams
KSA procurement teams and hospital pharmacy committees typically evaluate oncology medicines against international regulatory approvals — including those from the FDA and the European Medicines Agency (EMA) — as part of their due diligence process when considering products for local use. Key evaluation criteria include:
- Reference regulatory authority approvals (FDA, EMA, Health Canada, TGA)
- Manufacturing site compliance with international GMP standards
- Clinical evidence quality from pivotal registration trials
- Companion diagnostic availability for biomarker-driven therapies
- Post-marketing surveillance data and pharmacovigilance records
Important: Prospective buyers are advised to consult directly with the SFDA and their institutional regulatory affairs teams to confirm current local registration status and import requirements prior to procurement. Our team is available to support documentation and supply inquiries relevant to the Saudi Arabian market.
Safety Profile: Side Effects & Important Clinical Considerations
A thorough understanding of the talazoparib safety profile is critical for oncology pharmacists, medical affairs teams, and formulary decision-makers evaluating this PARP inhibitor for clinical use.
Common Adverse Reactions
The most frequently reported side effects associated with talazoparib reflect the hematologic and gastrointestinal profile characteristic of PARP inhibitor therapy and should be anticipated in clinical management planning:
Adverse Reactions (≥10% incidence in EMBRACA trial)
- Hematologic: Anemia (53%), neutropenia (49%), thrombocytopenia (39%), leukopenia (38%)
- Gastrointestinal: Nausea (49%), vomiting (32%), diarrhea (29%), decreased appetite (20%)
- General: Fatigue (53%), headache (21%)
- Dermatologic: Alopecia (38%)
Serious Risks and Warnings
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Clinically significant adverse events include myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), which have been reported in patients treated with talazoparib. In the EMBRACA trial, MDS/AML occurred in <1% of patients. However, the risk is well-established across the PARP inhibitor class, particularly in patients with prior exposure to chemotherapy or radiation.
Clinical Management:
- Monitor complete blood counts at baseline and monthly thereafter
- Discontinue talazoparib if MDS/AML is confirmed
- Refer patients with prolonged hematologic toxicities for hematologic assessment
Myelosuppression
Myelosuppression, including anemia, neutropenia, and thrombocytopenia, is common with talazoparib. These hematologic toxicities may be dose-limiting and can require dose modifications during the course of treatment. Grade 3 or 4 anemia occurred in 39% of patients in the EMBRACA trial, with 37% requiring red blood cell transfusions.
Embryo-Fetal Toxicity
Embryo-fetal toxicity has been identified as a serious risk. Based on its mechanism of action and findings in animals, talazoparib can cause fetal harm when administered to pregnant women. Appropriate contraceptive counseling is required for patients of reproductive potential:
- Females: Use effective contraception during treatment and for 7 months after the final dose
- Males with female partners: Use effective contraception during treatment and for 4 months after the final dose
- Pregnancy testing: Verify pregnancy status prior to initiating treatment
Special Populations and Dose Modifications
Renal Impairment
Dose reduction is recommended for patients with moderate or severe renal impairment. Talazoparib is primarily eliminated renally, and exposure increases in patients with reduced kidney function:
- Mild renal impairment (CrCl 60-89 mL/min): No dose adjustment required
- Moderate renal impairment (CrCl 30-59 mL/min): A dose reduction is required, as determined by the treating physician per the approved label
- Severe renal impairment (CrCl 15-29 mL/min): A greater dose reduction is required, as determined by the treating physician per the approved label
- End-stage renal disease (CrCl <15 mL/min): Not recommended
Lactation Guidance
Women are advised not to breastfeed while receiving talazoparib and for one month following the last dose, in accordance with the official prescribing information. There are no data on the presence of talazoparib in human milk or its effects on the breastfed child or milk production.
Institutional Preparedness Requirements
Procurement and clinical teams should ensure that adequate monitoring protocols and supportive care resources are in place at institutions where talazoparib is to be administered:
- Laboratory monitoring: Capability for regular CBC monitoring and renal function assessment
- Transfusion services: Access to blood product support for anemia management
- Growth factor support: Availability of G-CSF for neutropenia management if needed
- Pharmacy expertise: Oncology pharmacy specialists familiar with PARP inhibitor management
- Patient education: Resources for counseling on adverse effects and contraception requirements
All specific dosing decisions, including any modifications, must be determined by the treating physician in accordance with the full prescribing information.
Why Source Talaparib Through Our Bangladesh Supply Chain?
As a specialist B2B pharmaceutical supplier, we provide procurement teams, hospital pharmacies, oncology distributors, and tender managers in Saudi Arabia and across the Middle East with access to Bangladeshi-manufactured oncology medicines — including Talaparib capsules produced by Everest Pharmaceuticals Ltd.
Bangladesh Pharmaceutical Manufacturing Sector
Bangladesh has established a credible pharmaceutical manufacturing sector with a growing number of producers supplying internationally validated active pharmaceutical ingredients. The country’s pharmaceutical industry is characterized by:
- WHO GMP-certified facilities meeting international manufacturing standards
- Cost-competitive production enabling favorable pricing for institutional buyers
- Established export infrastructure serving markets across Asia, Africa, and the Middle East
- Growing oncology portfolio including targeted therapies and supportive care medicines
Everest Pharmaceuticals Ltd. manufactures Talaparib in both 0.25 mg and 1 mg capsule strengths, providing the product range required to support clinical programs involving this PARP inhibitor.
Supply Chain Capabilities for Middle East Markets
Our supply chain is structured to serve the specific requirements of the Middle East market, including the Kingdom of Saudi Arabia. We support a range of procurement models — including direct hospital supply, distributor partnerships, and government or institutional tender fulfillment — ensuring flexibility for buyers operating across different procurement frameworks.
Key Service Features
- Regulatory documentation support: Certificate of Pharmaceutical Product (CPP), GMP certificates, analytical certificates
- Cold chain management: Temperature-controlled logistics where required
- Flexible order quantities: Supporting both pilot programs and large-scale institutional procurement
- Tender response capability: Experienced in government and institutional tender processes
- Quality assurance: Batch-specific documentation and traceability
Comprehensive Oncology Portfolio
For institutions building out precision oncology formularies, our portfolio extends to other targeted agents. Teams evaluating broader oncology pipelines may also wish to review our supply capabilities for additional EGFR-targeted therapies and other molecularly defined cancer treatments, enabling consolidated sourcing for comprehensive cancer care programs.
Procurement Inquiry Process
To inquire about availability, lead times, and supply terms for Talaparib capsules in Saudi Arabia or the wider Middle East region, please contact our procurement team directly. We are equipped to respond to formal tender inquiries, provide product documentation, and support the sourcing process from initial inquiry through to delivery.
Our team understands the regulatory and logistical requirements specific to Saudi Arabian healthcare institutions and can provide guidance on documentation requirements, import procedures, and supply timelines relevant to your procurement framework.
Frequently Asked Questions
What is talazoparib used for?
Talazoparib is used to treat adult patients with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer as a single agent, and in combination with enzalutamide for adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer. Both indications are defined by specific genetic alterations, reflecting talazoparib’s role as a precision oncology therapy. Patient selection for the breast cancer indication requires confirmation of a germline BRCA mutation using an approved companion diagnostic test (BRACAnalysis CDx). The prostate cancer indication similarly requires documentation of HRR gene mutations through validated testing methods.
Is talazoparib approved for breast cancer?
Yes, talazoparib received FDA approval in October 2018 for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. This approval was supported by pivotal trial data from the EMBRACA study showing a statistically significant improvement in progression-free survival compared with standard chemotherapy (hazard ratio 0.54, p<0.0001). Eligibility for this indication requires testing with the BRACAnalysis CDx companion diagnostic to confirm the presence of a germline BRCA mutation. The FDA granted Priority Review designation for this application, recognizing the significant unmet need in this patient population.
What are the common side effects of talazoparib?
The most frequently reported side effects of talazoparib include fatigue (53%), anemia (53%), nausea (49%), neutropenia (49%), thrombocytopenia (39%), alopecia (38%), vomiting (32%), diarrhea (29%), headache (21%), and decreased appetite (20%). Serious risks include myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myelosuppression, and embryo-fetal toxicity, which may require dose modifications or additional clinical management. Grade 3 or 4 anemia occurred in 39% of patients in the pivotal trial, with 37% requiring red blood cell transfusions. Patients should be monitored closely throughout treatment with regular complete blood counts, and all dosing decisions must be made by the treating physician in accordance with the full prescribing information.
What is the clinical evidence supporting talazoparib in breast cancer?
In the pivotal breast cancer trial (EMBRACA), talazoparib achieved a median progression-free survival of 8.6 months compared with 5.6 months for patients receiving standard chemotherapy (physician’s choice of capecitabine, eribulin, gemcitabine, or vinorelbine), corresponding to a hazard ratio of 0.54 (95% CI: 0.41–0.71; p<0.0001). This statistically significant result represented a clinically meaningful 46% reduction in the risk of disease progression or death in patients with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. The EMBRACA study was a Phase 3, randomized, open-label, multicenter trial involving 431 patients. These findings formed the basis of the FDA approval granted in October 2018 and support its inclusion in precision oncology formularies worldwide.
Can procurement teams in Saudi Arabia source Talaparib through your supply chain?
Yes, we supply Talaparib capsules — manufactured by Everest Pharmaceuticals Ltd. in Bangladesh — to procurement teams, hospital pharmacies, oncology distributors, and tender managers in Saudi Arabia and across the wider Middle East region. We support multiple procurement models, including direct hospital supply, distributor partnerships, and institutional tender fulfillment. Our supply chain is structured to meet the specific regulatory and logistical requirements of the Saudi Arabian market, including provision of Certificate of Pharmaceutical Product (CPP), GMP certificates, and other documentation required for SFDA processes. Procurement teams are encouraged to contact us directly for information on availability, lead times, pricing, and supply documentation tailored to their institutional requirements.
What product documentation is available to support institutional procurement of Talaparib?
Our team is equipped to provide comprehensive product documentation relevant to institutional and government procurement processes in Saudi Arabia and the Middle East, including support for formal tender inquiries. Available documentation includes Certificate of Pharmaceutical Product (CPP), WHO GMP certificates for the manufacturing facility, batch-specific certificates of analysis, stability data, and product specifications. Talaparib capsules are manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and are available in both 0.25 mg and 1 mg capsule strengths, aligned with the internationally validated talazoparib molecule. Prospective buyers are also advised to consult the Saudi Food and Drug Authority (SFDA) and their internal regulatory affairs teams to confirm local registration and import requirements prior to procurement. We can support the documentation process for SFDA registration and import licensing as needed.
- 1. www.accessdata.fda.gov
- 2. www.fda.gov
- 3. www.accessdata.fda.gov
- 4. www.drugs.com
- 5. www.accessdata.fda.gov
Access This Medicine Through Saif Pharma
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in June 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.